Mobile

A phase 2, multicenter, open-label, single arm, two-stage study to evaluate the efficacy and safety of CC-4047 (Pomalidomide) in patients with advanced soft tissue sarcomas who have relapsed or are re...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-005670-31

A phase 2, multicenter, open-label, single arm, two-stage study to evaluate the efficacy and safety of CC-4047 (Pomalidomide) in patients with advanced soft tissue sarcomas who have relapsed or are refractory to systemic anticancer therapy

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the efficacy of CC-4047

Critère d'inclusion

  • Locally recurrent, unresectable or metastatic soft tissue sarcomas relapsed or refractory to doxorubicin and ifosfamide chemotherapy

Liens